How Veeva Works with IQVIA

How Veeva Works with IQVIA

Included here is a summary of the status of our lawsuit against IQVIA, how we work with IQVIA today, and what all of this means for customers.

Veeva’s antitrust lawsuit against IQVIA, filed in 2017, is still moving ahead. Due to COVID-related delays and the complexity of the case, the expected jury trial date is now in 2024. We are confident in our case and are committed to ending IQVIA’s anti-competitive practices that are harming the industry.

Veeva is not changing our approach or retaliating against IQVIA’s monopoly abuse tactics. Veeva has always believed in openness and customer choice, and customers can continue to expect that from Veeva. This means:

  • IQVIA Ability to Access Veeva Software – Allowed with No Change. IQVIA is still able to access all Veeva software applications, including Vault and CRM, provided a restricted software access agreement (RSAA) is signed to protect Veeva’s intellectual property. IQVIA requests that we issue new RSAAs to them regularly. We have not denied any IQVIA request for an RSAA to date and currently have more than 100 RSAAs in place with IQVIA. This program will not change.
  • IQVIA Ability to Access Veeva Data – Allowed with No Change. We also continue to sign TPAs to allow IQVIA to use Veeva’s data products, such as Veeva OpenData, with IQVIA’s software products and services. This program will not change.
  • Veeva CRO Partner Program – IQVIA Has Chosen Not to Participate. Veeva invited IQVIA to join the Veeva CRO partner program and have worked diligently since July 2020 to have them participate in the program in support of our joint customers. IQVIA is the only large CRO that has chosen not to join the program.

What does this mean for customers using IQVIA for clinical services with Veeva technology and why has IQVIA chosen not to join the CRO partner program?

  • Since IQVIA elected not to join the program, they are not able to build clinical studies in Vault CDMS. Study building is a complex and critical part of running a clinical trial. The CRO partner program provides CROs the needed Veeva Vault CDMS training, support, and resources necessary to ensure customer success.
  • There are many options for building studies in Veeva CDMS. Customers can use other Veeva CRO partners, Veeva services, or internal resources.
  • The CRO partner program requires that partners sign a simple agreement that sets out the terms of the program and also allows Veeva to participate in any software or data access programs the CRO offers to other companies. IQVIA has refused to join because agreeing would mean they are required to treat Veeva fairly and allow customer choice when it comes to software and data.

We hope this provides clarity. For further questions related to Veeva’s stance on any of the matters above, please ask your Veeva account executive.

Additionally, IQVIA issued an intentionally misleading press release on May 10, 2021, about a discovery ruling that has now been appealed by Veeva. If you have further detailed questions about the discovery ruling mentioned in IQVIA’s May 10, 2021 press release, please read the following FAQs.